JP3436547B2 - 頭蓋脳外傷後の二次的神経細胞損傷および機能疾患を治療するためのキサンチン誘導体の使用 - Google Patents

頭蓋脳外傷後の二次的神経細胞損傷および機能疾患を治療するためのキサンチン誘導体の使用

Info

Publication number
JP3436547B2
JP3436547B2 JP18328592A JP18328592A JP3436547B2 JP 3436547 B2 JP3436547 B2 JP 3436547B2 JP 18328592 A JP18328592 A JP 18328592A JP 18328592 A JP18328592 A JP 18328592A JP 3436547 B2 JP3436547 B2 JP 3436547B2
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
xanthine
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP18328592A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05186350A (ja
Inventor
ハンス−ペーター・シユーベルト
ジヨン・ジエイ・グロウム
バルバーラ・キトナー
カール・ルードルフイ
ウルリツヒ・ゲーベルト
Original Assignee
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JPH05186350A publication Critical patent/JPH05186350A/ja
Application granted granted Critical
Publication of JP3436547B2 publication Critical patent/JP3436547B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP18328592A 1991-07-11 1992-07-10 頭蓋脳外傷後の二次的神経細胞損傷および機能疾患を治療するためのキサンチン誘導体の使用 Expired - Lifetime JP3436547B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4122884 1991-07-11
DE4122884:7 1991-07-11
DE4217639 1992-05-28
DE4217639:5 1992-05-28

Publications (2)

Publication Number Publication Date
JPH05186350A JPH05186350A (ja) 1993-07-27
JP3436547B2 true JP3436547B2 (ja) 2003-08-11

Family

ID=25905369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18328592A Expired - Lifetime JP3436547B2 (ja) 1991-07-11 1992-07-10 頭蓋脳外傷後の二次的神経細胞損傷および機能疾患を治療するためのキサンチン誘導体の使用

Country Status (20)

Country Link
US (1) US5409935A (enExample)
EP (1) EP0528164B1 (enExample)
JP (1) JP3436547B2 (enExample)
KR (1) KR100237945B1 (enExample)
AT (1) ATE138573T1 (enExample)
AU (1) AU649851B2 (enExample)
CA (1) CA2073633C (enExample)
CZ (2) CZ81696A3 (enExample)
DE (1) DE59206403D1 (enExample)
DK (1) DK0528164T3 (enExample)
ES (1) ES2088519T3 (enExample)
GR (1) GR3020233T3 (enExample)
HU (1) HU217983B (enExample)
IE (1) IE74888B1 (enExample)
IL (1) IL102456A (enExample)
MX (1) MX9203323A (enExample)
PH (1) PH30341A (enExample)
RU (1) RU2126407C1 (enExample)
SK (1) SK280537B6 (enExample)
TW (1) TW210285B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
DK0584347T3 (da) * 1992-03-04 2003-02-24 Cell Therapeutics Inc Enantiomere hydroxylerede xanthinforbindelser
US5567704A (en) * 1992-03-04 1996-10-22 Cell Therapeutics, Inc. R-enatiomerically pure hydroxylated xanthine compounds to treat baldness
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
US5981536A (en) * 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
PL209573B1 (pl) * 2000-01-14 2011-09-30 Schering Ag Benzimidazole i zastosowanie benzimidazoli do wytwarzania środka leczniczego do leczenia lub zapobiegania chorobom związanym z aktywowaniem mikrogleju i środek farmaceutyczny zawierający benzimidazol
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
US7329679B2 (en) 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
DE60327628D1 (de) * 2002-06-12 2009-06-25 Hoffmann La Roche Amid substituierte xanthin derivate mit gluconeogenesis modulierender wirkung
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2330742C2 (de) * 1973-06-16 1982-07-29 Hoechst Ag, 6000 Frankfurt 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
CH608236A5 (enExample) * 1974-01-22 1978-12-29 Wuelfing J A Fa
US4275064A (en) * 1976-02-06 1981-06-23 Interx Research Corporation Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents
FR2531085A1 (fr) * 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
JPS6110715A (ja) * 1984-06-26 1986-01-18 Fanuc Ltd 絶対位置検出方式
JPH062675B2 (ja) * 1985-04-05 1994-01-12 ヘキストジヤパン株式会社 記憶障害治療剤
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IT1197516B (it) * 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
IT1229195B (it) * 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
GB8929208D0 (en) * 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｃｕｒｒ．Ｃｌｉｎ．Ｐｒａｃｔ．Ｓｅｒ．，１９８５年，Ｖｏｌ．１９，ｐ．４５９−４６１
Ｊ．Ｃｈｅｍ．Ｓｏｃ．，１９４５年，ｐ．７５１−７６０

Also Published As

Publication number Publication date
HU217983B (hu) 2000-05-28
ATE138573T1 (de) 1996-06-15
IL102456A (en) 1996-10-16
CA2073633C (en) 2003-09-23
MX9203323A (es) 1994-07-29
AU649851B2 (en) 1994-06-02
CZ282140B6 (cs) 1997-05-14
TW210285B (enExample) 1993-08-01
EP0528164A3 (enExample) 1994-03-02
RU94027686A (ru) 1996-05-27
DK0528164T3 (da) 1996-09-30
JPH05186350A (ja) 1993-07-27
IE74888B1 (en) 1997-08-13
HU9202273D0 (en) 1992-10-28
CA2073633A1 (en) 1993-01-12
SK280537B6 (sk) 2000-03-13
EP0528164A2 (de) 1993-02-24
HUT61763A (en) 1993-03-01
GR3020233T3 (en) 1996-09-30
SK216092A3 (en) 1995-09-13
CZ81696A3 (en) 1997-05-14
IL102456A0 (en) 1993-01-14
RU2126407C1 (ru) 1999-02-20
CZ281480B6 (cs) 1996-10-16
DE59206403D1 (de) 1996-07-04
AU1959192A (en) 1993-01-14
US5409935A (en) 1995-04-25
CZ216092A3 (en) 1993-01-13
EP0528164B1 (de) 1996-05-29
KR930001911A (ko) 1993-02-22
KR100237945B1 (ko) 2000-02-01
ES2088519T3 (es) 1996-08-16
IE922259A1 (en) 1993-01-13
PH30341A (en) 1997-04-02

Similar Documents

Publication Publication Date Title
RU2159231C2 (ru) 2,4-ДИСУЛЬФОНИЛ-α-ФЕНИЛ-ТРЕТ-БУТИЛНИТРОН, ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ, ЕГО ФОРМА СВОБОДНОЙ КИСЛОТЫ ИЛИ СОЛЕВАЯ ФОРМА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ
JP3436547B2 (ja) 頭蓋脳外傷後の二次的神経細胞損傷および機能疾患を治療するためのキサンチン誘導体の使用
EP0811623B1 (de) Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten
DE69622532T2 (de) Glycoprotein iib/iiia-antagonisten
JPH0136819B2 (enExample)
JPH03503162A (ja) 化学療法における毒性特性の改良
US4085214A (en) Stable pro-drug forms of theophylline
JP2567593B2 (ja) イミダゾリジントリオン誘導体及び該化合物を有効成分として含有するアレルギ−性疾患治療剤
CN112457291B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
EP0266559A2 (en) Therapeutic agent for the treatment of peptic ulcer disease
EP0442348B1 (de) Neue Imidazolverbindungen, Verfahren zu deren Herstellung, Arzneimittel auf Basis dieser Verbindungen sowie einige Zwischenprodukte
JP2002513789A (ja) １−（６−クロロナフト−２−イルスルホニル）−４−［４−（４−ピリジル）ベンゾイル］ピペラジンの細かい粒子サイズ形
JPS61126026A (ja) イソキノリンスルホン酸アミドを有効成分とする抗癌剤
RU2834322C1 (ru) Соли бензотиопиранонового соединения, способ их получения и применения
CN115073446B (zh) 小檗碱型生物碱氧化吡嗪甲酸季铵盐及其制备药物的用途
US3900564A (en) Ocotea alkaloid for relief of anxiety
US7345079B2 (en) Treatment of disorder related to low cyclic GMP levels
JPH11130672A (ja) 脂質過酸化抑制剤
JPH03145464A (ja) 光学活性１，４―ジヒドロピリジン誘導体
JPH03218378A (ja) キサンチン誘導体
JPH06107546A (ja) Ａｄｍ耐性解除剤
NL8006341A (nl) Voor roentgenstralen amorfe, fysiologisch toelaatbare zuuradditiezouten van ergotalkaloiden en dihydroer- gotalkaloiden, werkwijze voor de bereiding en toepas- sing daarvan in de therapie.
JPH0656833A (ja) 血液循環の中断による神経損傷を治療するためのキサンチン誘導体の使用
JPH0613518B2 (ja) 新規ピリミドピリミジン誘導体、その製法並びに該化合物を含有する医薬組成物
DE19636882A1 (de) Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20030430

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080606

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090606

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100606

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110606

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110606

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120606

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120606

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130606

Year of fee payment: 10

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130606

Year of fee payment: 10